Franklin Genomic Advancements Etf Current Valuation
| HELX Etf | USD 30.89 0.34 1.11% |
Valuation analysis of Franklin Genomic Adv helps investors to measure Franklin Genomic's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that Franklin Genomic's price fluctuation is very steady at this time. Calculation of the real value of Franklin Genomic Adv is based on 3 months time horizon. Increasing Franklin Genomic's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Franklin Genomic is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Franklin Etf. However, Franklin Genomic's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 30.89 | Real 30.92 | Hype 30.9 |
The intrinsic value of Franklin Genomic's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Franklin Genomic's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Franklin Genomic Advancements helps investors to forecast how Franklin etf's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Franklin Genomic more accurately as focusing exclusively on Franklin Genomic's fundamentals will not take into account other important factors: Franklin Genomic Advancements ETF Current Valuation Analysis
Franklin Genomic's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Franklin Genomic Advancements has a Current Valuation of 0.0. This indicator is about the same for the Franklin Templeton Investments average (which is currently at 0.0) family and about the same as Health (which currently averages 0.0) category. This indicator is about the same for all United States etfs average (which is currently at 0.0).
Franklin Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Franklin Genomic's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the etfs which would be a good addition to a portfolio. Peer analysis of Franklin Genomic could also be used in its relative valuation, which is a method of valuing Franklin Genomic by comparing valuation metrics of similar companies.Franklin Genomic is currently under evaluation in current valuation as compared to similar ETFs.
Fund Asset Allocation for Franklin Genomic
The fund consists of 98.96% investments in stocks, with the rest of investments allocated between various types of exotic instruments.Asset allocation divides Franklin Genomic's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
Franklin Fundamentals
| Beta | 1.14 | |||
| Total Asset | 10.39 M | |||
| One Year Return | 11.90 % | |||
| Three Year Return | (14.70) % | |||
| Net Asset | 10.39 M | |||
| Equity Positions Weight | 98.96 % |
About Franklin Genomic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Franklin Genomic Advancements's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Franklin Genomic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Franklin Genomic Advancements based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Franklin Genomic Adv offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Franklin Genomic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Franklin Genomic Advancements Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Franklin Genomic Advancements Etf:Check out Franklin Genomic Piotroski F Score and Franklin Genomic Altman Z Score analysis. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
The market value of Franklin Genomic Adv is measured differently than its book value, which is the value of Franklin that is recorded on the company's balance sheet. Investors also form their own opinion of Franklin Genomic's value that differs from its market value or its book value, called intrinsic value, which is Franklin Genomic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Franklin Genomic's market value can be influenced by many factors that don't directly affect Franklin Genomic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Franklin Genomic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Franklin Genomic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Franklin Genomic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.